Sign in →

Test Code AATHR Thrombophilia Profile, Plasma and Whole Blood


Ordering Guidance


Multiple coagulation profile tests are available. See Coagulation Profile Comparison for testing that is performed with each profile.



Shipping Instructions


Send all specimens in the same shipping container.



Specimen Required


Both blood and plasma are required.

 

Patient Preparation:

1. Patient should not be receiving Coumadin (warfarin), heparin, direct thrombin inhibitors (argatroban, dabigatran), or direct factor Xa inhibitors (apixaban, rivaroxaban, and edoxaban).

2. Specimen must be collected prior to initiation of anticoagulants and thrombolytic therapy.

3. If patient has been recently transfused, it is best to perform this study pretransfusion, if possible.

 

Specimen Type: Whole blood

Container/Tube:

Preferred: Lavender top (EDTA)

Acceptable: Yellow top (ACD), light-blue top (3.2% sodium citrate)

Specimen Volume: 3 mL

Collection Instructions:

1. Invert several times to mix blood.

2. Send whole blood specimen in original tube. Do not aliquot.

3. Label specimen as whole blood.

 

Specimen Type: Platelet-poor plasma

Collection Container/Tube: Light-blue top (3.2% sodium citrate)

Submission Container/Tube: Plastic vial (polypropylene preferred)

Specimen Volume: 5 mL in 5 plastic vials; each containing 1 mL

Collection Instructions:

1. Specimen must be collected prior to factor replacement therapy.

2. For complete instructions, see Coagulation Guidelines for Specimen Handling and Processing.

3. Centrifuge, transfer all plasma into a plastic vial, and centrifuge plasma again.

4. Aliquot plasma (1-2 mL per aliquot) into 5 separate plastic vials leaving 0.25 mL in the bottom of centrifuged vial.

5. Freeze plasma immediately (no longer than 4 hours after collection) at -20° C or, ideally, -40° C or below.

Additional Information: Double-centrifuged specimen is critical for accurate results as platelet contamination may cause spurious results.


Useful For

Evaluating patients with thrombosis or hypercoagulability states

 

Detecting a lupus-like anticoagulant; dysfibrinogenemia; disseminated intravascular coagulation/intravascular coagulation and fibrinolysis

 

Detecting a deficiency of antithrombin, protein C, or protein S

 

Detecting activated protein C resistance (and the factor V Leiden [p.Arg534Gln, historically known as R506Q] variant if indicated)

 

Detecting the prothrombin F2 c.*97G>A variant (historically known as G20210A)

Profile Information

Test ID Reporting Name Available Separately Always Performed
AATHI Thrombophilia Interpretation No Yes
PTSC Prothrombin Time (PT), P Yes, (order PTTP) Yes
APTSC Activated Partial Thrombopl Time, P Yes, (order APTTP) Yes
DRV1 Dilute Russells Viper Venom Time, P Yes, (order DRVI1) Yes
TTSC Thrombin Time (Bovine), P Yes Yes
CLFIB Fibrinogen, Clauss, P Yes, (order FIBTP) Yes
DIMER D-Dimer, P Yes, (order DDITT) Yes
ATTF Antithrombin Activity, P Yes Yes
CFX Protein C Activity, P Yes Yes
PSF Protein S Ag, Free, P Yes, (order PSTF) Yes
APCRV Activated Protein Resistance V, P Yes Yes
PTNT Prothrombin G20210A Mutation, B Yes Yes

Reflex Tests

Test ID Reporting Name Available Separately Always Performed
ATTI Antithrombin Antigen, P Yes No
FACTV Coag Factor V Assay, P Yes No
F_7 Coag Factor VII Assay, P Yes No
F_9 Coag Factor IX Assay, P Yes No
F_10 Coag Factor X Assay, P Yes No
F_11 Coag Factor XI Assay, P Yes No
F_12 Coag Factor XII Assay, P Yes No
F8A Coag Factor VIII Activity Assay, P Yes No
RTSC Reptilase Time, P Yes No
F_2 Coag Factor II Assay, P Yes No
PCAG Protein C Ag, P Yes No
F5DNA Factor V Leiden (R506Q) Mutation, B Yes No
PNP Platelet Neutralization Procedure No No
PTMSC PT Mix 1:1 No No
APMSC APTT Mix 1:1 No No
PST Protein S Ag, Total, P No No
DRV2 DRVVT Mix No No
DRV3 DRVVT Confirmation No No
SOLFM Soluble Fibrin Monomer No No
PTFIB PT-Fibrinogen, P No No
HEXLA HEX LA, P No No
SFX Protein S Activity, P Yes No

Method Name

PTSC, APTSC, DRV1, TTSC, APCRV: Optical Clot-Based

CLFIB: Clauss

DIMER, PSF: Latex Immunoassay (LIA)

ATTF, CFX: Chromogenic

PTNT: Direct Variant Analysis

AATHI: Medical Interpretation

Reporting Name

Thrombophilia Prof

Specimen Type

Plasma Na Cit
Whole blood

Specimen Minimum Volume

Plasma: 5 mL total, 5 plastic vials each containing 1 mL, Whole blood: 1 mL

Specimen Stability Information

Specimen Type Temperature Time Special Container
Plasma Na Cit Frozen 14 days
Whole blood Ambient (preferred) 14 days
  Frozen  14 days
  Refrigerated  14 days

Reject Due To

Gross hemolysis Reject
Gross lipemia Reject
Gross icterus Reject

Clinical Information

Thrombophilia is defined as an acquired or familial disorder associated with thrombosis. The clinical presentation of an underlying thrombophilia predominantly includes venous thromboembolism (deep vein thrombosis, pulmonary embolism, superficial vein thrombosis). Other manifestations that have been linked to thrombophilia include recurrent miscarriage and complications of pregnancy (eg, severe preeclampsia, abruptio placentae, intrauterine growth restriction, stillbirth). Thrombophilia does not predict arterial thrombosis. Demographic or environmental exposures that compound the risk of venous thromboembolism among persons with a thrombophilia include increasing age, male gender, obesity, surgery, trauma, hospitalization for medical illness, malignant neoplasm, prolonged immobility during travel (eg, prolonged airplane travel), oral contraceptive use, estrogen therapy (both oral and transdermal), tamoxifen and raloxifene therapy, and infertility drugs. Central venous catheters and transvenous pacemaker wires increase the risk for upper extremity deep vein thrombosis; this risk is unrelated to thrombophilia.

 

Inherited thrombophilias include:

-Deficiency due to reduced plasma protein level or dysfunctional protein of:

-Antithrombin

-Protein C

-Protein S

-Dysfibrinogenemias (rare)

-Activated protein C resistance due to the factor V Leiden variant (F5 c.1601G>A; p.Arg534Gln, historically known as R506Q)

-Prothrombin F2 c.*97G>A variant (historically known as G20210A)

 

Acquired thrombophilias include a lupus-like anticoagulant (antiphospholipid antibodies) and disseminated intravascular coagulation/intravascular coagulation and fibrinolysis (DIC/ICF). DIC/ICF may cause thrombotic as well as hemorrhagic events. Positive tests for DIC/ICF can also occur as consequences of thrombosis.

 

Acquired deficiencies of fibrinogen, protein C, protein S, and antithrombin may be found in conjunction with liver disease (they are produced by the liver) or DIC/ICF and are of uncertain significance with respect to thrombosis risk.

 

Acquired deficiencies of protein C and protein S are also found in patients with liver disease who are being treated with oral anticoagulants (eg, warfarin, Coumadin), since both proteins are dependent upon the action of vitamin K for normal function.

 

Acquired protein S deficiency also occurs in thrombotic thrombocytopenic purpura, pregnancy or estrogen therapy, nephrotic syndrome, and sickle cell anemia. In acute illness, the levels of acute-phase reactants rise (including C4b binding protein, which binds and inactivates protein S in the plasma), and the portion of bound protein S also rises, leaving a lower proportion of free protein S. The significance of acquired protein S deficiency with respect to thrombosis risk is unknown.

Reference Values

An interpretive report will be provided.

Day(s) Performed

Weekly

Report Available

4 to 7 days

Performing Laboratory

Mayo Clinic Laboratories in Rochester

Test Classification

See Individual Test IDs

CPT Code Information

81240-F2 PTNT

85300-ATTF

85303-CFX

85306-PSF

85307-APCRV

85379-DIMER

85384-CLFIB

85390-26-AATHI

85610-PTSC

85613-DRV1

85670-TTSC

85730-APTSC

81241-F5 (coagulation factor V) (eg, hereditary hypercoagulability) gene analysis, Leiden variant (if appropriate)

85210-Factor II (if appropriate)

85220-Factor V (if appropriate)

85230-Factor VII (if appropriate)

85240-Factor VIII (if appropriate)

85250-Factor IX (if appropriate)

85260-Factor X (if appropriate)

85270-Factor XI (if appropriate)

85280-Factor XII (if appropriate)

85301-Antithrombin antigen (if appropriate)

85302-Protein C antigen (if appropriate)

85305-Protein S antigen, total (if appropriate)

85306-Protein S activity (if appropriate)

85366-Soluble fibrin monomer (if appropriate)

85385-PT-Fibrinogen (if appropriate)

85597-Platelet neutralization for lupus inhibitor (if appropriate)

85598-Hex LA (if appropriate)

85611-PT mix 1:1 (if appropriate)

85613-DRVVT mix (if appropriate)

85613-DRVVT confirmation (if appropriate)

85635-Reptilase (if appropriate)

85732 - APTT Mix 1:1 (if appropriate)